Looking ahead, the future growth of affordable medicine in Germany will be significantly fueled by the patent expirations of major biologic drugs and the subsequent introduction of biosimilars. Biologics, which are high-cost, high-value therapies, represent a massive cost-saving opportunity once they face generic-like competition. Biosimilars—which are essentially the generic equivalent...

In early 2026, the nationwide adoption of the e-prescription (e-Rezept) has provided the generic industry with a goldmine of real-time data to optimize production and distribution. These 2026 digital systems allow manufacturers to see exactly which medications are being prescribed in which regions, enabling them to ship supplies where they are most needed and reducing the incidence of "expired"...